Viruses 2010, 2(8), 1734-1751; doi:10.3390/v2081734
Review

Core as a Novel Viral Target for Hepatitis C Drugs

1 Department of Infectology, The Scripps Research Institute-Scripps Florida, 130 Scripps Way, Jupiter, FL-33458, USA 2 Department of Chemistry, The Center for Chemical Methodology and Library Development, Boston University, Boston, MA 02215, USA
* Author to whom correspondence should be addressed.
Received: 18 June 2010; in revised form: 6 August 2010 / Accepted: 16 August 2010 / Published: 20 August 2010
(This article belongs to the Special Issue Antivirals Against Hepatitis C Virus)
PDF Full-text Download PDF Full-Text [290 KB, uploaded 20 August 2010 17:18 CEST]
Abstract: Hepatitis C virus (HCV) infects over 130 million people worldwide and is a major cause of liver disease. No vaccine is available. Novel specific drugs for HCV are urgently required, since the standard-of-care treatment of pegylated interferon combined with ribavirin is poorly tolerated and cures less than half of the treated patients. Promising, effective direct-acting drugs currently in the clinic have been described for three of the ten potential HCV target proteins: NS3/NS4A protease, NS5B polymerase and NS5A, a regulatory phosphoprotein. We here present core, the viral capsid protein, as another attractive, non-enzymatic target, against which a new class of anti-HCV drugs can be raised. Core plays a major role in the virion’s formation, and interacts with several cellular proteins, some of which are involved in host defense mechanisms against the virus. This most conserved of all HCV proteins requires oligomerization to function as the organizer of viral particle assembly. Using core dimerization as the basis of transfer-of-energy screening assays, peptides and small molecules were identified which not only inhibit core-core interaction, but also block viral production in cell culture. Initial chemical optimization resulted in compounds active in single digit micromolar concentrations. Core inhibitors could be used in combination with other HCV drugs in order to provide novel treatments of Hepatitis C.
Keywords: Hepatitis C Virus; HCV; core dimerization; peptide inhibitors; small molecule inhibitors; virus assembly

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Strosberg, A.D.; Kota, S.; Takahashi, V.; Snyder, J.K.; Mousseau, G. Core as a Novel Viral Target for Hepatitis C Drugs. Viruses 2010, 2, 1734-1751.

AMA Style

Strosberg AD, Kota S, Takahashi V, Snyder JK, Mousseau G. Core as a Novel Viral Target for Hepatitis C Drugs. Viruses. 2010; 2(8):1734-1751.

Chicago/Turabian Style

Strosberg, Arthur Donny; Kota, Smitha; Takahashi, Virginia; Snyder, John K.; Mousseau, Guillaume. 2010. "Core as a Novel Viral Target for Hepatitis C Drugs." Viruses 2, no. 8: 1734-1751.

Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert